Citizens Maintains Market Outperform on MBX Biosciences, Raises Price Target to $86

Benzinga Newsdesk www.benzinga.com Positive 91.3%

Neg 0% Neu 0% Pos 91.3%

Citizens analyst Jonathan Wolleben maintains MBX Biosciences (NASDAQ:MBX) with a Market Outperform and raises the price target from $76 to $86.